Cargando…
Resistance to paclitaxel is associated with a variant of the gene BCL2 in multiple tumor types
Paclitaxel, the most commonly used form of chemotherapy, is utilized in curative protocols in different types of cancer. The response to treatment differs among patients. Biological interpretation of a mechanism to explain this personalized response is still unavailable. Since paclitaxel is known to...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478919/ https://www.ncbi.nlm.nih.gov/pubmed/31044156 http://dx.doi.org/10.1038/s41698-019-0084-3 |